Convalescent Plasma Therapy in Patients With COVID-19
Launched by BIOFARMA · May 28, 2020
Trial Information
Current as of May 02, 2025
Completed
Keywords
ClinConnect Summary
The rational use of antibodies from the recovered patient's plasma as a natural neutralizing antibody to the cell-infected virus (plaques). Several expanded use of convalescent plasma therapy to severe and/or critically ill COVID-19 patients had been done in the US and China. Investigator reported that 5 patients received convalescent plasma, three patients were successfully discharged and 2 patients improved.
Based on the previous study, investigators initiate an intervention study with purposes to produce quality convalescent plasma from the recovered patients and to find an alternative ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed COVID-19 case with RT-PCR
- • Stage IIb of COVID-19 or higher
- • Consent was given by the patient or legal guardian
- Exclusion Criteria:
- • Pregnant
- • History of anaphylactic reaction in previous blood product transfusion
About Biofarma
Biofarma is a leading biopharmaceutical company dedicated to advancing healthcare through innovative therapeutic solutions. With a strong focus on research and development, Biofarma specializes in the discovery and commercialization of biologics and biosimilars that address unmet medical needs across various therapeutic areas. Committed to quality and patient safety, the company adheres to rigorous regulatory standards and employs cutting-edge technology to ensure the efficacy and reliability of its products. Biofarma collaborates with healthcare professionals and research institutions globally to facilitate clinical trials and bring transformative therapies to market, enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jakarta Pusat, , Indonesia
Patients applied
Trial Officials
Nana Sarnadi, Sp.OG
Study Director
director of research and develpment
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials